Drug Type Exosomes |
Synonyms ILB 323, ILB323 |
Target |
Action inhibitors |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuralgia | Preclinical | South Korea | 01 Nov 2024 | |
| Pain | Preclinical | South Korea | 07 Feb 2023 |





